Background Glioblastoma is the most common and most lethal form of brain tumor in human. Unfortunately, there is still no effective therapy to this fatal disease and the median survival is generally less than one year from the time of diagnosis. Discovery of ligands that can bind specifically to this type of tumor cells will be of great significance to develop early molecular imaging, targeted delivery and guided surgery methods to battle this type of brain tumor. Methodology/Principal Findings We discovered two target-specific aptamers named GBM128 and GBM131 against cultured human glioblastoma cell line U118-MG after 30 rounds selection by a method called cell-based Systematic Evolution of Ligands by EXponential enrichment (cell-SELEX). These two aptamers have high affinity and specificity against target glioblastoma cells. They neither recognize normal astraglial cells, nor do they recognize other normal and cancer cell lines tested. Clinical tissues were also tested and the results showed that these two aptamers can bind to different clinical glioma tissues but not normal brain tissues. More importantly, binding affinity and selectivity of these two aptamers were retained in complicated biological environment. Conclusion/Significance The selected aptamers could be used to identify specific glioblastoma biomarkers. Methods of molecular imaging, targeted drug delivery, ligand guided surgery can be further developed based on these ligands for early detection, targeted therapy, and guided surgery of glioblastoma leading to effective treatment of glioblastoma.
References
[1]
Ohgaki H, Kleihues P (2005) Population-Based Studies on Incidence, Survival Rates, and Genetic Alterations in Astrocytic and Oligodendroglial Gliomas. J Neuropathol Exp Neurol 64: 479–489.
[2]
Castro MG, Cowen R, Williamson IK, David A, Jimenez-Dalmaroni MJ, et al. (2003) Current and future strategies for the treatment of malignant brain tumors. Pharmacol Ther 98: 71–108.
[3]
Laperriere NJ, Bernstein M (1994) Radiotherapy for brain tumors. CA Cancer J Clin 44: 96–108.
[4]
Ng H–K, Lam PYP (1998) The molecular genetics of central nervous system tumors. Pathology 30: 196–202.
Curran WJ Jr, Scott CB, Horton J, Nelson JS, Weinstein AS, et al. (1993) Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst 85: 704–710.
[7]
Osborne SE, Ellington AD (1997) Nucleic Acid Selection and the Challenge of Combinatorial Chemistry. Chem Rev 97: 349–370.
[8]
Wilson DS, Szostak JW (1999) In vitro selection of functional nucleic acids. Annu Rev Biochem 68: 611–647.
[9]
Rupcich N, Chiuman W, Nutiu R, Mei S, Flora KK, et al. (2005) Quenching of Fluorophore-Labeled DNA Oligonucleotides by Divalent Metal Ions: Implications for Selection, Design, and Applications of Signaling Aptamers and Signaling Deoxyribozymes. J Amer Chem Soc 128: 780–790.
[10]
Osborne SE, Matsumura I, Ellington AD (1997) Aptamers as therapeutic and diagnostic reagents: problems and prospects. Curr Opin Chem Biol 1: 5–9.
[11]
Famulok M, Hartig JS, Mayer G (2007) Functional aptamers and aptazymes in biotechnology, diagnostics, and therapy. Chem Rev 107: 3715–3743.
[12]
Navani NK, Li Y (2006) Nucleic acid aptamers and enzymes as sensors. Curr Opin Chem Biol 10: 272–281.
[13]
Jiang Y, Zhu C, Ling L, Wan L, Fang X, et al. (2003) Specific aptamer-protein interaction studied by atomic force microscopy. Anal Chem 75: 2112–2116.
[14]
Dua P, Kim S, Lee D-K (2011) Nucleic acid aptamers targeting cell-surface proteins. Methods 54: 215–225.
[15]
Mallikaratchy P, Tang Z, Kwame S, Meng L, Shangguan D, et al. (2007) Aptamer Directly Evolved from Live Cells Recognizes Membrane Bound Immunoglobin Heavy Mu Chain in Burkitt's Lymphoma Cells. Mol Cell Proteomics 6: 2230–2238.
[16]
Shangguan D, Li Y, Tang Z, Cao ZC, Chen HW, et al. (2006) Aptamers evolved from live cells as effective molecular probes for cancer study. Proc Nat Acad Sci 103: 11838–11843.
[17]
Ireson CR, Kelland LR (2006) Discovery and development of anticancer aptamers. Mol Cancer Ther 5: 2957–2962.
[18]
Ellington AD, Szostak JW (1990) In vitro selection of RNA molecules that bind specific ligands. Nature 346: 818–822.
[19]
Tuerk C, Gold L (1990) Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 249: 505–510.
[20]
Sefah K, Shangguan D, Xiong X, O'Donoghue MB, Tan W (2010) Development of DNA aptamers using Cell-SELEX. Nat Protoc 5: 1169–1185.
[21]
Blank M, Weinschenk T, Priemer M, Schluesener H (2001) Systematic Evolution of a DNA Aptamer Binding to Rat Brain Tumor Microvessels. J Biol Chem 276: 16464–16468.
[22]
Shangguan D, Cao Z, Meng L, Mallikaratchy P, Sefah K, et al. (2008) Cell-specific aptamer probes for membrane protein elucidation in cancer cells. J Proteome Res 7: 2133–2139.
[23]
Mallikaratchy P, Tang Z, Kwame S, Meng L, Shangguan D, et al. (2007) Aptamer directly evolved from live cells recognizes membrane bound immunoglobin heavy mu chain in Burkitt's lymphoma cells. Mol Cell Proteomics 6: 2230–2238.
[24]
Thiel WH, Bair T, Wyatt Thiel K, Dassie JP, Rockey WM, et al. (2011) Nucleotide Bias Observed with a Short SELEX RNA Aptamer Library. Nucleic Acid Ther 21: 253–263.
[25]
Shangguan D, Li Y, Tang Z, Cao ZC, Chen HW, et al. (2006) Aptamers evolved from live cells as effective molecular probes for cancer study. Proc Natl Acad Sci U S A 103: 11838–11843.
[26]
Tang Z, Shangguan D, Wang K, Shi H, Sefah K, et al. (2007) Selection of aptamers for molecular recognition and characterization of cancer cells. Anal Chem 79: 4900–4907.
[27]
Bayrac AT, Sefah K, Parekh P, Bayrac C, Gulbakan B, et al. (2011) In vitro Selection of DNA Aptamers to Glioblastoma Multiforme. ACS Chem Neurosci 2: 175–181.
[28]
Fang XH, Tan WH (2010) Aptamers Generated from Cell-SELEX for Molecular Medicine: A Chemical Biology Approach. Accounts of Chemical Research 43: 48–57.
[29]
Iliuk AB, Hu L, Tao WA (2011) Aptamer in bioanalytical applications. Analytical Chemistry 83: 4440–4452.
[30]
Pu Y, Zhu Z, Liu HX, Zhang JN, Liu J, et al. (2010) Using aptamers to visualize and capture cancer cells. Analytical and Bioanalytical Chemistry 397: 3225–3233.
[31]
Soule HD, Maloney TM, Wolman SR, Peterson WD, Brenz R, et al. (1990) Isolation and characterization of a spontaneously immortalized human breast epithelial cell line, MCF-10. Cancer Res 50: 6075.
[32]
Guo KT, Sch？fer R, Paul A, Gerber A, Ziemer G, et al. (2006) A New Technique for the Isolation and Surface Immobilization of Mesenchymal Stem Cells from Whole Bone Marrow Using High – Specific DNA Aptamers. Stem Cells 24: 2220–2231.
[33]
Thompson JD, Gibson TJ, Plewniak F, Jeanmougin F, Higgins DG (1997) The CLUSTAL_X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools. Nucleic Acids Research 25: 4876–4882.
[34]
Chen HW, Medley CD, Sefah K, Shangguan D, Tang Z, et al. (2008) Molecular Recognition of Small – Cell Lung Cancer Cells Using Aptamers. ChemMedChem 3: 991–1001.
[35]
Zhao Z, Xu L, Shi X, Tan W, Fang X, et al. (2009) Recognition of subtype non-small cell lung cancer by DNA aptamers selected from living cells. Analyst 134: 1808–1814.
